1 Nov 2010
Author(s): 
PATH

Since the introduction in 2006 of the Malaria Vaccine Technology Roadmap, intended to align and guide the malaria vaccine community, the primary goal of the PATH Malaria Vaccine Initiative (MVI) has been the development of a vaccine for Plasmodium falciparum with at least 80 percent efficacy against clinical malaria in children through age five. Hence, a key component of MVI’s research and development strategy is to build on the success of GlaxoSmithKline Vaccines’ RTS,S malaria vaccine candidate, now in Phase 3 clinical trial at 11 sites throughout Africa, the first and only malaria vaccine candidate to reach this stage.